Hims & Hers Health rises 10.2% after class-action notices prompt investor interest

What happened

Hims & Hers Health (HIMS) rose 10.2% on October 9, 2026, after multiple law firms and shareholder services circulated notices of a securities class action. The notices covered purchases between August 4, 2025, and July 29, 2026, and urged affected investors to seek lead plaintiff status by the November 2, 2026, deadline, according to GlobeNewsWire and Zacks Investment Research. The stock closed at $30.92. Trading volume was 1.6 times its 20-day average, and the stock opened 1.0% above the previous close.

How big was the move

The stock rose 10.2% on the day, a move that was 1.9 times a typical daily move for this stock. That outpaced the Healthcare sector median, which rose 1.4% on the day, by 8.8 percentage points. The S&P 500 rose 0.6% on October 9, 2026, and rose 1.1% over the last five sessions. The stock itself rose 6.6% over those five sessions. Market sensitivity remains elevated with a beta of 2.50, so the stock tends to move more than the market.

Trading volume was higher than recent norms. In the past five years the stock had 48 sessions with a gain of at least 10.2%. Twenty trading days later the median result was a gain of 4.5%, and 27 of 48 were higher. Taken together, the session looked like a large, mostly company-specific move that followed the circulation of legal notices.

The technical picture

The stock traded 6.5% above its 20-day moving average and 5.0% above its 50-day moving average. It was 12.9% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend. The stock had been above the 200-day average for 16 consecutive trading days. The Relative Strength Index (14 days) stood at 57, within a neutral range between 30 and 70, so short-term momentum looks constructive.

That said, the stock remained 52.6% below the 52-week high and had fallen 46.8% over one year. It trailed the S&P 500 by 62.5 percentage points over the same period. Volatility was high at 85% annualized over 60 days, higher than 68% of its own readings over five years, indicating investors should expect wide swings.

Fundamentals and valuation

For the four quarters through June 30, 2026, Hims & Hers Health reported revenue of $2.58 billion, which grew 28.0% from a year earlier. Revenue growth one quarter earlier was growth of 32.8%. Diluted earnings per share were $-0.63, with earnings per share growth from a year earlier that fell 178.3%.

Gross margin narrowed to 64.7% from 76.2% a year earlier, and operating margin fell to 3.6% from 6.2% a year earlier. Free-cash-flow margin stood at 3.5% and return on invested capital was 3.7%. Share count over one year decreased by 9.7%. The free-cash-flow yield was 1.4%.

Taken together, the figures show solid top-line expansion but compressed profitability and modest cash returns. Revenue growth of 28.0% contrasts with the negative diluted earnings per share, reflecting margin pressure and the company’s current path toward profitability. The decrease in gross and operating margins implies cost or mix challenges that have materially affected the bottom line and free-cash-flow yield.

Earnings and analyst expectations

Hims & Hers Health is scheduled to report next on November 9, 2026. The last report, on August 10, 2026, showed earnings per share of $-0.37 against $-0.05 expected, 643.1% below estimates. Typical two-day reactions after recent reports saw the stock rose 1.3%.

The company has recorded 0 consecutive quarters beating estimates and an average surprise over the last four reports of 100.0% below estimates. Analysts give a consensus rating of Hold. Thirty-five percent of analysts rate the stock Buy. The consensus price target is $32.17, which is 4.0% above the closing price on October 9, 2026, based on 20 analysts with ratings.

Analyst coverage and forthcoming quarterly results will likely guide near-term sentiment, particularly as investors weigh whether margins and cash generation can recover. With the consensus price target only modestly above the recent close, market-moving upward revisions would likely require clear evidence of margin improvement or a strategic update from management.

What to watch

• November 9, 2026: next scheduled earnings report.
• The November 2, 2026, deadline for lead plaintiff status in the securities class action notices issued covering purchases between August 4, 2025, and July 29, 2026.
• Short-term technical levels: the stock is 6.5% above its 20-day moving average and 5.0% above its 50-day moving average.
• Conference and regulatory disclosures that could follow the class-action notices and any material updates to revenue or margin guidance.
• Analysts’ revisions and changes to the consensus price target, currently $32.17.